Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2012

01.03.2012 | Original Article

Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study

verfasst von: Nina Mortazavi-Jehanno, Anne-Laure Giraudet, Laurence Champion, Florence Lerebours, Elise Le Stanc, Veronique Edeline, Olivier Madar, Dominique Bellet, Alain Paul Pecking, Jean-Louis Alberini

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this pilot study was to assess whether outcome in metastatic or recurrent breast cancer patients is related to metabolic response to endocrine therapy determined by 18F-FDG PET/CT.

Methods

The study group comprised 22 patients with breast cancer (age 58 ± 11 years, mean ± SD) who were scheduled to receive endocrine therapy. They were systematically assessed by PET/CT at baseline and after a mean of 10 ± 4 weeks for evaluation of response after induction. All patients demonstrated FDG-avid lesions on the baseline PET/CT scan. The metabolic response was assessed according to EORTC criteria and based on the mean difference in SUVmax between the two PET/CT scans, and the patients were classified into four groups: complete or partial metabolic response, or stable or progressive metabolic disease (CMR, PMR, SMD and PMD, respectively). All patients were followed in our institution.

Results

Metastatic sites were localized in bone (n = 15), lymph nodes (n = 11), chest wall (n = 3), breast (n = 5), lung (n = 3), soft tissue (n = 1) and liver (n = 1). PMR was observed in 11 patients (50%), SMD in 5 (23%) and PMD in 6 (27%). The median progression-free survival (PFS) times were 20, 27 and 6 months in the PMR, SMD and PMD groups, respectively. PFS in the SMD group differed from that in the PMR and SMD groups (p < 0.0001).

Conclusion

Metabolic response assessed by FDG PET/CT imaging in patients with metastatic breast cancer treated with endocrine therapy is predictive of the patients’ PFS.
Literatur
1.
Zurück zum Zitat Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Heinemann V, et al.; Central European Cooperative Oncology Group (CECOG). Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20:1771–85.PubMedCrossRef Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Heinemann V, et al.; Central European Cooperative Oncology Group (CECOG). Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20:1771–85.PubMedCrossRef
2.
Zurück zum Zitat Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14:2584–9.PubMed Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14:2584–9.PubMed
3.
Zurück zum Zitat Kaufmann M, von Minckwitz G, Bear H, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927–34.PubMedCrossRef Kaufmann M, von Minckwitz G, Bear H, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927–34.PubMedCrossRef
4.
Zurück zum Zitat Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689–95.PubMed Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689–95.PubMed
5.
Zurück zum Zitat Smith I, Welch A, Hutcheon A, Miller I, Payne S, Chilcott F. Positron emission tomography using [(18)]-(fluorine-18)-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676–88.PubMed Smith I, Welch A, Hutcheon A, Miller I, Payne S, Chilcott F. Positron emission tomography using [(18)]-(fluorine-18)-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676–88.PubMed
6.
Zurück zum Zitat Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366–72.PubMedCrossRef Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366–72.PubMedCrossRef
7.
Zurück zum Zitat Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915–24.PubMedCrossRef Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915–24.PubMedCrossRef
8.
Zurück zum Zitat McDermott G, Welch A, Staff R, Gilbert F, Schweiger L, Semple S, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat. 2007;102(1):75–84.PubMedCrossRef McDermott G, Welch A, Staff R, Gilbert F, Schweiger L, Semple S, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat. 2007;102(1):75–84.PubMedCrossRef
9.
Zurück zum Zitat Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535–41.PubMedCrossRef Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535–41.PubMedCrossRef
10.
Zurück zum Zitat Duch J, Fuster D, Munoz M, Fernandez PL, Paredes P, Fontanillas M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1551–7.PubMedCrossRef Duch J, Fuster D, Munoz M, Fernandez PL, Paredes P, Fontanillas M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1551–7.PubMedCrossRef
11.
Zurück zum Zitat Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005;46:1144–50.PubMed Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005;46:1144–50.PubMed
12.
Zurück zum Zitat Couturier O, Jerusalem G, N’Guyen J, Hustinx R. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006;12:6437–43.PubMedCrossRef Couturier O, Jerusalem G, N’Guyen J, Hustinx R. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006;12:6437–43.PubMedCrossRef
13.
Zurück zum Zitat Specht J, Tam S, Kurland B, Gralow J, Livingston R, Linden H, et al. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat. 2007;105:87–94.PubMedCrossRef Specht J, Tam S, Kurland B, Gralow J, Livingston R, Linden H, et al. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat. 2007;105:87–94.PubMedCrossRef
14.
Zurück zum Zitat Dehdashti F, Flanagan F, Mortimer J, Katzenellenbogen J, Welch M, Siegel B. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51–6.PubMedCrossRef Dehdashti F, Flanagan F, Mortimer J, Katzenellenbogen J, Welch M, Siegel B. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51–6.PubMedCrossRef
15.
Zurück zum Zitat Mortimer J, Dehdashti F, Siegel B, Trinkaus K, Katzenellenbogen J, Welch M. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797–803.PubMed Mortimer J, Dehdashti F, Siegel B, Trinkaus K, Katzenellenbogen J, Welch M. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797–803.PubMed
16.
Zurück zum Zitat Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82.PubMedCrossRef Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82.PubMedCrossRef
17.
Zurück zum Zitat Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
18.
Zurück zum Zitat Hamaoka T, Madewell J, Podoloff D, Hortobagyi G, Ueno N. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–53.PubMedCrossRef Hamaoka T, Madewell J, Podoloff D, Hortobagyi G, Ueno N. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–53.PubMedCrossRef
19.
Zurück zum Zitat Du Y, Cullum I, Illidge T, Ell P. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007;25:3440–7.PubMedCrossRef Du Y, Cullum I, Illidge T, Ell P. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007;25:3440–7.PubMedCrossRef
20.
Zurück zum Zitat Tateishi U, Gamez C, Dawood S, Yeung H, Cristofanilli M, Macapinlac H. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of systemic therapy with integrated PET/CT. Radiology. 2008;247:189–96.PubMedCrossRef Tateishi U, Gamez C, Dawood S, Yeung H, Cristofanilli M, Macapinlac H. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of systemic therapy with integrated PET/CT. Radiology. 2008;247:189–96.PubMedCrossRef
21.
Zurück zum Zitat Schneider-Kolsky M, Hart S, Fox J, Midolo P, Stuckey J, Hofman M, et al. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res. 2010;12:R37.PubMedCrossRef Schneider-Kolsky M, Hart S, Fox J, Midolo P, Stuckey J, Hofman M, et al. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res. 2010;12:R37.PubMedCrossRef
22.
Zurück zum Zitat Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, et al. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. 2010;16:660–2. Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, et al. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. 2010;16:660–2.
23.
Zurück zum Zitat Bos R, van Der Hoeven J, van Der Wall E, van Der Groep P, van Diest P, Comans E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;15:379–87.CrossRef Bos R, van Der Hoeven J, van Der Wall E, van Der Groep P, van Diest P, Comans E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;15:379–87.CrossRef
24.
Zurück zum Zitat Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317–23.PubMedCrossRef Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317–23.PubMedCrossRef
25.
Zurück zum Zitat Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14:260–8.PubMedCrossRef Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14:260–8.PubMedCrossRef
26.
Zurück zum Zitat Smith I, Dowsett M, Ebbs S, Dixon J, Skene A, Blohmer J, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–16.PubMedCrossRef Smith I, Dowsett M, Ebbs S, Dixon J, Skene A, Blohmer J, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–16.PubMedCrossRef
27.
Zurück zum Zitat Dowsett M, Smith I, Ebbs S, Dixon J, Skene A, Griffith C, et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006;12:1024s–30s.PubMedCrossRef Dowsett M, Smith I, Ebbs S, Dixon J, Skene A, Griffith C, et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006;12:1024s–30s.PubMedCrossRef
28.
Zurück zum Zitat Dowsett M, Smith I, Ebbs S, Dixon J, Skene A, A’Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167–70.PubMedCrossRef Dowsett M, Smith I, Ebbs S, Dixon J, Skene A, A’Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167–70.PubMedCrossRef
29.
Zurück zum Zitat Huyge V, Garcia C, Alexiou J, Ameye L, Vanderlinden B, Lemort M, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol). 2010;22:818–27.CrossRef Huyge V, Garcia C, Alexiou J, Ameye L, Vanderlinden B, Lemort M, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol). 2010;22:818–27.CrossRef
30.
Zurück zum Zitat Champion L, Brain E, Giraudet A, Le Stanc E, Wartski M, Edeline V, et al. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer. 2011;117:1621–9.PubMedCrossRef Champion L, Brain E, Giraudet A, Le Stanc E, Wartski M, Edeline V, et al. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer. 2011;117:1621–9.PubMedCrossRef
31.
Zurück zum Zitat Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.PubMedCrossRef Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.PubMedCrossRef
32.
Zurück zum Zitat Ellis M, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–16.PubMed Ellis M, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–16.PubMed
33.
Zurück zum Zitat Mintun M, Welch M, Siegel B, Mathias C, Brodack J, McGuire A, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45–8.PubMed Mintun M, Welch M, Siegel B, Mathias C, Brodack J, McGuire A, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45–8.PubMed
34.
Zurück zum Zitat McGuire A, Dehdashti F, Siegel B, Lyss A, Brodack J, Mathias C, et al. Positron tomographic assessment of 16a-[18F]fluoro-17b-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526–31.PubMed McGuire A, Dehdashti F, Siegel B, Lyss A, Brodack J, Mathias C, et al. Positron tomographic assessment of 16a-[18F]fluoro-17b-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526–31.PubMed
35.
Zurück zum Zitat Linden H, Stekhova S, Link J, Gralow J, Livingston R, Ellis G, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793–9.PubMedCrossRef Linden H, Stekhova S, Link J, Gralow J, Livingston R, Ellis G, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793–9.PubMedCrossRef
36.
Zurück zum Zitat Dehdashti F, Mortimer J, Trinkaus K, Naughton M, Ellis M, Katzenellenbogen J, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2009;113:509–17.PubMedCrossRef Dehdashti F, Mortimer J, Trinkaus K, Naughton M, Ellis M, Katzenellenbogen J, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2009;113:509–17.PubMedCrossRef
37.
Zurück zum Zitat Ko B, Paik J, Jung K, Lee K. 17b-Estradiol augments 18F-FDG uptake and glycolysis of T47D breast cancer cells via membrane-initiated rapid PI3K-Akt activation. J Nucl Med. 2010;51:1740–7.PubMedCrossRef Ko B, Paik J, Jung K, Lee K. 17b-Estradiol augments 18F-FDG uptake and glycolysis of T47D breast cancer cells via membrane-initiated rapid PI3K-Akt activation. J Nucl Med. 2010;51:1740–7.PubMedCrossRef
38.
Zurück zum Zitat Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36–42.PubMedCrossRef Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36–42.PubMedCrossRef
39.
Zurück zum Zitat Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[(18)F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339–47.PubMedCrossRef Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[(18)F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339–47.PubMedCrossRef
40.
Zurück zum Zitat Lindholm P, Lapela M, Någren K, Lehikoinen P, Minn H, Jyrkkiö S. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun. 2009;30:30–6.PubMedCrossRef Lindholm P, Lapela M, Någren K, Lehikoinen P, Minn H, Jyrkkiö S. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun. 2009;30:30–6.PubMedCrossRef
Metadaten
Titel
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study
verfasst von
Nina Mortazavi-Jehanno
Anne-Laure Giraudet
Laurence Champion
Florence Lerebours
Elise Le Stanc
Veronique Edeline
Olivier Madar
Dominique Bellet
Alain Paul Pecking
Jean-Louis Alberini
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1981-z

Weitere Artikel der Ausgabe 3/2012

European Journal of Nuclear Medicine and Molecular Imaging 3/2012 Zur Ausgabe